OrSense is a medical device company founded in 1997 and headquartered in Israel. The company is focused on developing and marketing non-invasive monitoring systems for the measurement of Hemoglobin. OrSense's flagship product, the NBM200 system, has been successfully installed in dozens of blood donation facilities worldwide. The company's cutting-edge products are based on a proprietary Occlusion Spectroscopy technology. The latest round of funding for OrSense took place as a Series H investment on 11 February 2015, with Saints Capital participating as the investors. This investment signifies ongoing confidence in the company's innovative approach to non-invasive medical monitoring. For more information, interested parties can visit OrSense's website at www.orsense.com.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series H | Unknown | 1 |
|
11 Feb 2015 |
| Series H | Unknown | 1 |
|
16 Apr 2014 |
| Debt Financing | Unknown | 1 |
|
23 Jan 2014 |
| Venture Round | $18.00M | 3 |
|
02 May 2011 |
| Series C | $8.20M | 3 |
|
15 Aug 2001 |
We care about your data, and we'd love to use cookies make your experience better.
